Literature DB >> 21062258

The crosstalk between the matrix metalloprotease system and the chemokine network in acute myeloid leukemia.

K J Hatfield1, H Reikvam, Ø Bruserud.   

Abstract

Matrix metalloproteinases (MMPs) comprise a large family of zinc-dependent endopeptidases, which are best known for their ability to degrade essentially all components of the extracellular matrix (ECM). By breaking down ECM, MMPs may remove physical barriers, thus allowing cells to migrate and potentially invade other tissues. Recent evidence, however, shows that the proteolytic activities of MMPs also affect several fundamental physiological processes. Primary human acute myeloid leukemia (AML) cells often show constitutive release of several MMPs and chemokines, and there seems to be a crosstalk between the MMP system and the chemokine network. Firstly, the nuclear factor-κB (NF-κB) system represents a common regulator at the transcriptional level both for MMPs (e.g. MMP-1 and MMP-9) and for the constitutive release of several chemokines (CCL2-4/CXCL1/8) by primary human AML cells. Secondly, the crosstalk at the molecular level probably includes MMP-mediated structural alteration and activation of constitutively released chemokines involved in AML cell migration (e.g. CXCL12) and stimulation of bone marrow angiogenesis (e.g. CXCL8). Thirdly, at a functional level the two systems interact because the chemokine network plays a role in similar physiological processes as the MMPs, including AML cell proliferation and migration and local regulation of angiogenesis. Both the chemokine system and MMPs are currently being evaluated as targets in anti-angiogenesis/cancer therapy and may also have potential therapeutic implications in AML. This review introduces the different members of the MMP family and describes their interactions with the chemokine network and the possible involvement of MMPs together with chemokines in leukemogenesis and chemosensitivity in AML.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21062258     DOI: 10.2174/092986710794183033

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  32 in total

1.  The constitutive protease release by primary human acute myeloid leukemia cells.

Authors:  Maria Honnemyr; Øystein Bruserud; Annette K Brenner
Journal:  J Cancer Res Clin Oncol       Date:  2017-06-19       Impact factor: 4.553

2.  An extracellular matrix signature in leukemia precursor cells and acute myeloid leukemia.

Authors:  Valerio Izzi; Juho Lakkala; Raman Devarajan; Heli Ruotsalainen; Eeva-Riitta Savolainen; Pirjo Koistinen; Ritva Heljasvaara; Taina Pihlajaniemi
Journal:  Haematologica       Date:  2017-04-14       Impact factor: 9.941

3.  Diallyl disulfide inhibits TNFα-induced CCL2 release by MDA-MB-231 cells.

Authors:  David Bauer; Elizabeth Mazzio; Karam Fa Soliman; Equar Taka; Ebenezer Oriaku; Tracey Womble; Selina Darling-Reed
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

4.  Diallyl disulfide inhibits TNFα induced CCL2 release through MAPK/ERK and NF-Kappa-B signaling.

Authors:  D Bauer; N Redmon; E Mazzio; E Taka; J S Reuben; A Day; S Sadrud-Din; H Flores-Rozas; K F A Soliman; S Darling-Reed
Journal:  Cytokine       Date:  2015-06-20       Impact factor: 3.861

Review 5.  The progress of angiogenic factors in the development of leukemias.

Authors:  Yang Han; Xidi Wang; Bingping Wang; Guosheng Jiang
Journal:  Intractable Rare Dis Res       Date:  2016-02

6.  Matrix metalloproteinase (MMP)-1 induces lung alveolar epithelial cell migration and proliferation, protects from apoptosis, and represses mitochondrial oxygen consumption.

Authors:  Iliana Herrera; José Cisneros; Mariel Maldonado; Remedios Ramírez; Blanca Ortiz-Quintero; Elena Anso; Navdeep S Chandel; Moisés Selman; Annie Pardo
Journal:  J Biol Chem       Date:  2013-07-31       Impact factor: 5.157

7.  Prognostic value of matrix metalloproteinase-1/ proteinase-activated receptor-1 signaling axis in hepatocellular carcinoma.

Authors:  Mingmei Liao; Ping Tong; Jinfeng Zhao; Yangde Zhang; Zhehai Li; Jiwei Wang; Xueping Feng; Man Hu; Yifeng Pan
Journal:  Pathol Oncol Res       Date:  2011-09-10       Impact factor: 3.201

8.  Ocimum gratissimum retards breast cancer growth and progression and is a natural inhibitor of matrix metalloproteases.

Authors:  Pratima Nangia-Makker; Tirza Raz; Larry Tait; Malathy P V Shekhar; Hong Li; Vitaly Balan; Hemanckur Makker; Rafael Fridman; Krishnarao Maddipati; Avraham Raz
Journal:  Cancer Biol Ther       Date:  2013-02-04       Impact factor: 4.742

9.  The CXCR4/SDF1 axis improves muscle regeneration through MMP-10 activity.

Authors:  Miriam Bobadilla; Neira Sainz; Gloria Abizanda; Josune Orbe; José Antonio Rodriguez; José Antonio Páramo; Felipe Prósper; Ana Pérez-Ruiz
Journal:  Stem Cells Dev       Date:  2014-03-14       Impact factor: 3.272

10.  Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer.

Authors:  Ruizhong Wang; Poornima Bhat-Nakshatri; Maria B Padua; Mayuri S Prasad; Manjushree Anjanappa; Max Jacobson; Courtney Finnearty; Victoria Sefcsik; Kyle McElyea; Rachael Redmond; George Sandusky; Narsimha Penthala; Peter A Crooks; Jianguo Liu; Teresa Zimmers; Harikrishna Nakshatri
Journal:  Mol Cancer Ther       Date:  2017-10-04       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.